For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
Scope of the Report:
Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
In the last several years, global market of Asparaginase developed stably, with an average growth rate of 1.4%. In 2017, global revenue of Asparaginase is nearly 390 M USD; the actual production is about 590 K Units.
The worldwide market for Asparaginase is expected to grow at a CAGR of roughly 1.3% over the next five years, will reach 410 million US$ in 2024, from 380 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Asparaginase in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Jazz Pharmaceuticals
- Shire
- Medac GmbH
- Kyowa Hakko Kirin
- Qianhong Bio-pharma
- Taj Pharmaceuticals
- Mingxing Pharma
- SL Pharma
- United Biotech
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Escherichia Coli
- Erwinia Chrysanthemi
- Pegylated
Market Segment by Applications, can be divided into
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Asparaginase product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Asparaginase, with price, sales, revenue and global market share of Asparaginase in 2017 and 2018.
Chapter 3, the Asparaginase competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Asparaginase breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Asparaginase market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Asparaginase sales channel, distributors, customers, research findings and conclusion, appendix and data source.